GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, ...

Copay misuse at the pharmacy isn't always intentional, but the cost to your program is the same either way. Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time ...

The most immediate impacts of the U.S.- Iran conflict is being observed in the supply of active pharmaceutical ingredients ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Gilead Sciences agreed to acquire Tubulis GmbH for upwards of $5 billion in a deal that significantly expands Gilead's oncology pipeline and establishes Munich as a dedicated antibody-drug conjugates ...

Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity ...

Intensifying pipeline competition and shorter differentiation windows demand faster, higher-precision launch decisions as most products fail to reach “international excellence” and many generate ...

World Health Day 2026’s theme of “Together for health, Stand with science,” arrives at a moment when scientific evidence is being tested across public health policy and drug development.

GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...